Skip to content
Open in App
Adicet Bio logo

Adicet Bio

web2

Adicet Bio is a clinical-stage biotechnology company developing engineered immune-cell therapie...

Symbol ยท ACET
Company profile

About

Adicet Bio is a clinical-stage biotechnology company developing engineered immune-cell therapies for autoimmune diseases and cancers, including treatments made from donor-derived gamma delta T cells. Its lead investigational therapy, prulacabtagene leucel or prula-cel, is a chimeric antigen receptor T-cell candidate being studied in lupus and other autoimmune conditions. Unlike treatments individually manufactured from each patient's cells, its allogeneic approach is intended to support an off-the-shelf supply. The company also researches cell therapies aimed at solid tumors and is developing an in vivo CAR T platform for additional indications. Its products remain in clinical or earlier development, rather than being approved medicines sold commercially.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: ACET
Expert coverage

Adicet Bio profile.

Orbitrum research

Expert coverage

No published expert evaluations are available for this project yet.

Orbitrum Academy

Learn how to read a project assessment